

PRINCIPLES OF ANTIBIOTIC USE

REBEKAH MOEHRING, MD, MPH; DUKE UNIVERSITY MEDICAL CENTER
 MEDICAL DIRECTOR, ANTIMICROBIAL STEWARDSHIP AND EVALUATION TEAM
 SPICE 2024

Duke University School of Medicine dcasip.medicine.duke.edu Duke Center for Antimicrobial Stewardship and Infection Prevention

1

Disclosures

Grants to Institution: CDC, AHRQ
 Royalties: UpToDate, Inc.

Acknowledgements:
 John Juliano, MD (UNC)
 Deverick Anderson, MD, MPH (Duke)
 Robin Jump, MD (Pittsburg VAMC)

Duke Center for Antimicrobial Stewardship and Infection Prevention

2

Objectives

Understand why antibiotics are "special" medications
 The 4 Moments of Antibiotic Decision-Making
 Antimicrobial Stewardship Programs
 "Action" strategies in different clinical settings

Duke Center for Antimicrobial Stewardship and Infection Prevention

3

We Love Antibiotics


Inpatient	Long-term Care	Outpatient
At any given time, 62% of inpatients at DUMC are receiving at least one antimicrobial	Up to 70% of residents in a nursing home receive one or more courses of systemic antibiotics when followed over a year	423-553 antibiotic prescriptions per 1000 people in the US per year
There are >24,000 antimicrobial admissions at DUMC annually DUMC spends >\$12 million on antimicrobial agents each year	40-75% of antibiotic prescriptions are inappropriate	30% are unnecessary, (representing 47 million prescriptions/year)

Duke Center for Antimicrobial Stewardship and Infection Prevention

4

Why We Love Antibiotics

Wonder Drug	Antibiotics are time-tested placebos
Active intervention	Antibiotic Rx is easy: <ul style="list-style-type: none"> Avoids doing a structured exam or long DDx Avoids time-consuming discussions i.e. Easier to treat than diagnose or educate
Experiences	Identifying Infected vs. Not Infected is hard
Tangible	"Just in case" perceived to be lower risk than "watchful waiting"
Insurance	



Duke Center for Antimicrobial Stewardship and Infection Prevention

5

Why we HAVE TO improve Antibiotic Use


Antibiotics are unlike any other drug, in that the use of the agent in one patient can compromise its efficacy in another.

A lot of antibiotic prescriptions are unnecessary or sub-optimal.

We are running out of antibiotics.

Antibiotic misuse harms patients.

Improving antibiotic use has many benefits for patients and society.




Slide adapted from Arjun Srinivasan, MD (CDC)

Duke Center for Antimicrobial Stewardship and Infection Prevention

6

Antimicrobial Use Impacts: Infection Prevention, HAIs, AND Patient Outcomes




- Drug-resistance (MRSA, VRE, CRE, MDR-GNs)
- C. difficile* infection
 - Infection treatment success/failure
 - Complications
 - Readmissions
 - Mortality
 - Length of Stay
- Adverse Safety Events
 - Allergic reactions
 - Drug toxicity events
 - Acute Kidney Injury
- Healthcare Resources and Cost
 - (all of the above)
 - Pharmacy budget; ICU days

Duke Center for Antimicrobial Stewardship and Infection Prevention

7

One in Five Inpatients get an Antibiotic Adverse Drug Event

1488 patients followed for 30 days after antibiotic initiation
 Followed 90 days for CDI and MDRO acquisition
 General medical inpatients who had at least 24h of antibiotics during admission
20% of patients experienced at least one antibiotic-associated ADE



Organ System	Percentage
GI	24%
MDRO	26%
C. difficile	17%
Renal	14%
Heme	9%
Liver	4%
Other/Neuro	4%
Cardiac	9%

Tamma et al. JAMA Int Med. 2017 177(9):1308-15.

Duke Center for Antimicrobial Stewardship and Infection Prevention

8

A case

86F with history of dementia, diabetes, and poor functional status presents from SNF with confusion, fever.

ED: Hypotense, non-verbal. Fluid resuscitated, cultures drawn, started on vancomycin + zosyn and admitted to the floor with diagnosis of sepsis.

Day 3: Remains on vancomycin and zosyn, progress note still says "sepsis." BCx negative. Awake/interactive.

Urine culture: E. coli susceptible to multiple oral and intravenous agents.


Duke Center for Antimicrobial Stewardship and Infection Prevention

9

Making the Right Decision Is Important

Getting the correct antibiotic to our sickest patients in a timely manner is critical.

Inappropriate empiric antibiotics associated with increased mortality and longer length of stay.
 * In febrile inpatients, in ICU patients




In Septic Shock, each hour delay in administration of appropriate antimicrobials is associated with increased mortality.
 * Average decrease in survival of 7.6%/hour over the first 6h after shock onset

Surviving Sepsis Campaign

Fraser A, et al. Am J Med 2006;119:970-6
 Kollef, M, et al. Chest 1999. 115: 462-474
 Kumar et al. Crit Care Med. 2006 Jun;34(6):1589-96.

Duke Center for Antimicrobial Stewardship and Infection Prevention

10



Web Images Videos News Shopping Maps Books

About 69,564,000 results (0.81 seconds)

Did you mean: **vanc/zosyn**

Created with didyoumean-generator.com

Duke Center for Antimicrobial Stewardship and Infection Prevention

11

But, not for ALL infected patients

"Sepsis" without shock – a very heterogeneous population that does NOT show the same time-related associations with antibiotic/mortality


Sepsis can be hard to diagnose. Many patients with hypotension have non-infectious diagnoses.
 * pulmonary emboli, fluid under/overload, toxin exposures, drug adverse effects, malignancies, bleeding, mechanical complications of surgery, obstructed organs, etc....

Overly tight limits on timing of antibiotics for suspected sepsis may cause clinicians to err on the side of over-treatment, skip diagnostic steps, and subject patients to the harms of antibiotic overuse.


Weinberger et al. J Infect Dis. 2020 Jul 21;222(Suppl 2):S110-S118
 Liu VX. Am J Respir Crit Care Med 2017; 196:856–863
 Seymour CW, et al. N Engl J Med 2017; 376:2235–2244

Duke Center for Antimicrobial Stewardship and Infection Prevention

12



13



14

Good use of antibiotics requires balance. It's nuanced and complex.

Right Diagnosis

Right Drug

Right Dose

Right Timing

Right Duration

Improve therapeutic choices (underuse)

Reduce unnecessary use (overuse)

15

The "4 Moments" of Antibiotic Decision-Making

1. Does the patient have an infection that requires antibiotics?
2. Have I ordered appropriate cultures before starting antibiotics? What empirical antibiotic therapy should I initiate?
3. A day or more has passed. Can I stop antibiotics? Can I narrow therapy? Can I change from IV to oral therapy?
4. What duration of antibiotic therapy is needed for this patient's diagnosis?

Tamma PD et al. JAMA. 2019;321(2):139-140.

16

5 or 6 "Ds" of Antimicrobial Stewardship

Goebel et al. Clin Micro Rev 2021. <https://doi.org/10.1128/CMR.00003-20>

Diagnosis	Make and document the right diagnosis.
Drug	Use the right drug empiric antibiotic.
Dose	Use the right dose of antibiotic based on site of infection and renal or hepatic dysfunction.
Duration	Use antibiotics for the recommended duration.
De-escalation	De-escalate therapy based on susceptibilities and when urine cultures are negative.

Morency-Potvin, Schwartz, Weinstein. Clin Micro Rev 30: 381-407

Diagnosis: Make and document the right diagnosis.

Debridement/ Drainage: Drainage of abscesses and removal of necrotic tissue or foreign material when required.

Drug: Use the right drug empiric according to suspected or confirmed diagnosis, risk factors for resistant pathogens, allergy, or major side effects.

Dose: Use right dose according to diagnosis, site of infection, or renal/hepatic dysfunction.

Duration: Use drugs for an appropriate duration.

De-escalation: Re-evaluate diagnosis and therapy routinely and de-escalate therapy to narrow-spectrum and/or oral agents when appropriate.

17

Clinical information: Small pieces over time.

Clinical information trickles in over time. This means clinicians have to reassess regularly. This also means they get interrupted with 'real-time' notifications and need to respond. This is a complex process: unpredictable, unknowns, uncertainty.

Putting the puzzle together completely takes attention, follow up on details, ability to make decisions in the setting of unknowns, AND an eye on the long-term goals.

18

General Indications for Antibiotics

Prophylaxis: prevent infection
 • EASY! Guidelines and ordersets

Empiric: when you suspect infection but don't exactly know with what pathogen
 • Not easy. Local guidelines help (based on local micro data).

Directed: pathogen known
 • Moderately easy. Follow and interpret patient-specific micro data.

Duke Center for Antimicrobial Stewardship and Infection Prevention

19

Choice of Empiric Antimicrobials: Clinical Syndrome

What class of pathogen am I likely to be treating?
 • (Bacterial? Viral? Fungal? Other?)

If bacterial, what organisms are most likely?
 • (Gram positive? Gram negative? Anaerobe?)

What information can I get to guide treatment?
 • Microbiology data?

Do I need to order any other diagnostic tests?

How sick is my patient? How risky would it be if I miss?

Is my patient "special"? – allergy, ADEs, immune status

2

Have I ordered appropriate cultures before starting antibiotics?
 What empirical antibiotic therapy should I initiate?

Duke Center for Antimicrobial Stewardship and Infection Prevention

20

Traditional Microbiologic Culture

• "Gold standard" for diagnosis
 • Requires sampling of site of infection *prior to* therapy
 • Allows determination of phenotypic antimicrobial susceptibility

Growth? Up to 5 days

Duke Center for Antimicrobial Stewardship and Infection Prevention

21

DIAGNOSIS: Stain

Direct Visualization

Gram stain
 • Often provide clues to etiology (may allow presumptive diagnosis in some cases)
 • Gram Positive
 • Gram Negative
 • Non-staining

Shape
 • Cocci
 • Rods

Aerobic/Anaerobic

Duke Center for Antimicrobial Stewardship and Infection Prevention

www.laboratoryinfo.com

22

Quick and Dirty Anti-bacterial Classification

Gram positive – skin, lung, guts, devices
 Gram negative – guts, urine, some lung, chronic wounds
 Atypicals – lung, STIs
 Anaerobes –gas- and abscess-forming, bad odors
 Fungi – guts, devices, immunosuppressed + abx-exposed hosts

Duke Center for Antimicrobial Stewardship and Infection Prevention

23

GRAM POSITIVE ORGANISMS

Gram positive cocci
 • *Staphylococcus aureus*
 • Coagulase negative staphylococcus
 • *Streptococcus pneumoniae*
 • *Streptococcus* sp.
 • *Enterococcus* sp.

Gram positive rods
 • *Bacillus* sp. (aerobes)
 • *Clostridium* sp. (anaerobes)

Gram positive – skin, lung, guts, devices

MSSA: Cefazolin, Nafcillin/Oxacillin
 MRSA: Vancomycin, Daptomycin, TMP/SMX, Linezolid
 Strep: Penicillin, Ampicillin/Amoxicillin, Ceftriaxone
 Enterococci: Ampicillin, Vancomycin
 VRE: Daptomycin, Linezolid

Duke Center for Antimicrobial Stewardship and Infection Prevention

24

GRAM NEGATIVE ORGANISMS

Gram negative cocci

- Neisseria meningitidis
- Neisseria gonorrhoeae

Gram negative rods (enteric)

- E. coli
- Klebsiella sp.
- Enterobacter sp.
- Proteus sp.
- Serratia sp.



Gram negative rods (non-enteric, non-lactose fermenters)

- Pseudomonas aeruginosa
- Stenotrophomonas maltophilia
- Acinetobacter sp.

CA-Enterics:
Ceftriaxone
Quinolones
TMP/SMX


Gram- negative: guts, urine, some lung

Anti-pseudomonal or HA-Resistant Enterics:
Pip/tazo
Cefepime
Ceftazidime
(Carbapenem)

25

Antibiotics with Anti-anaerobic Activity




Class	Agents (Route)	B. fragilis susceptibility ^{1,2}
Beta-lactam beta-lactamase inhibitor combinations	amoxicillin/clav (PO)	90-97%
	ampicillin/sulb (IV)	97%
	piperacillin/tazo (IV)	> 99%
Cephalosporin	cefotetan (IV)	N/A
	cefoxitin (IV)	83-90%
Carbapenem	doripenem (IV)	> 99%
	ertapenem (IV/IM)	
	meropenem (IV) imipenem (IV)	
Fluoroquinolone	moxifloxacin (IV/PO)	66-70%
Other	clindamycin (IV/PO)	66-70%
	metronidazole (IV/PO)	> 99%
	tigecycline (IV)	81-96%

B. fragilis is the most common group of gut anaerobes.
Then GPRs (Clostridium spp.)

Also consider: mouth, vaginal sources

Gas- and abscess-forming, bad odors

C. difficile is a special case (oral vancomycin).



26

NON-STAINING Bacterial PATHOGENS

"Atypicals" -- Not stained by Gram's method (Intracellular)

- Legionella sp. (Antigen test of the urine)
- Chlamydia (PCR)
- Rickettsia (Serology or PCR)

Mycobacteria



- M. tuberculosis
- Non-tuberculous mycobacteria

Macrolides:
Azithromycin
Clarithromycin

Tetracyclines:
Doxycycline
Minocycline


Community-acquired pneumonia	Pathogens	CXR pattern
Typical pneumonia	Bacterial: S. Pneumoniae H. Influenzae	Lobar, dense
Atypical pneumonia	Viral: influenza, RSV Bacterial: Legionella Mycoplasma Chlamydia	Diffuse, patchy

Ziehl-Neelsen Stain of TB

27

Fungi



Candida/Yeast

- Fluconazole
- Echinocandins (micafungin, caspofungin)

Cryptococcus

- Amphotericin + flucytosine
- Fluconazole


Molds (Rhizopus/Mucor, Aspergillus)

- Voriconazole
- Posaconazole, Isavuconazole
- Itraconazole

<http://drfungus.org>

Guts, devices, immunosuppressed + abx-exposed hosts



MSG ERC
doctor fungus
Your online reference to all things mycological



28

DIAGNOSIS: Antigen Tests



- Very useful for following (and sometimes diagnosing) viral infections: HIV, HBV, COVID-19
- Occasionally useful for other pathogens (e.g., Cryptococcus)
- Quick/rapid tests are often based on antigen testing, less expensive
- Urine is sometimes used for antigen tests (e.g. Legionella urine antigen)
- Limitations: Less Sensitivity

29

DIAGNOSIS: Serology or Antibody Tests

- For bacterial infections, generally not useful in early diagnosis (usually requires acute and convalescent tests)
- For viral infections, IgM may allow early diagnosis (e.g., HepA)
- Works ok for difficult to access/culture pathogens
- Limitation: slower turnaround, cannot distinguish phase of illness
- E.g. Syphilis IgG -- after initial infection, test remains positive for lifetime

30

DIAGNOSIS: PCR and Molecular tests

- Highly sensitive
- Allows diagnosis of non-culturable pathogens (e.g., norovirus)
- Limitations: Subject to false positives (e.g. *C. difficile* colonization vs. infection?)
- Rapid turnaround time
- Increasing use of Syndromic Panel tests (e.g. blood, respiratory, CSF, GI) that also include resistance genes
- E.g. Blood culture + GNR – get pathogen ID and molecular resistance gene targets within 1-2 hours

Duke Center for Antimicrobial Stewardship and Infection Prevention

31

Pathogens are tricky.

Susceptibility

Serratia marcescens	MIC	S
Amikacin		R
Ampicillin		R
Ampicillin + Sulbactam		R
Cefazolin		R
Ceftriaxone		S
Ciprofloxacin		I
Gentamicin		S
Piperacillin/Tazobactam		S
Tobramycin		S
Trimethoprim + Sulfamethoxazole		S

Antibiotic = A drug that kills or inhibits the growth of bacterial pathogens

Resistant = Designation that implies that an antimicrobial will not inhibit bacterial growth at clinically achievable concentrations

Susceptible = Designation that implies that an antimicrobial will inhibit bacterial growth at clinically achievable concentrations

Duke Center for Antimicrobial Stewardship and Infection Prevention

32

MIC = Minimal inhibitory concentration. Lowest concentration of antimicrobial that inhibits growth of bacteria. Commonly used in clinical lab

Breakpoint = The MIC that is used to designate between susceptible and resistant.

Intrinsic vs. Acquired

Known quantity of bacteria placed into each tube

Increasing antibiotic concentration

Duke Center for Antimicrobial Stewardship and Infection Prevention

33

Mechanisms of Action of Antibiotics

Duke Center for Antimicrobial Stewardship and Infection Prevention

34

Patients are individuals.

Drug interactions

Age

Allergies

Pregnancy, breast feeding

Toxicity (idiosyncratic reactions)

Dose adjustment for renal and/or hepatic dysfunction

Ability to absorb an oral antibiotic

Immune status

Adherence:

- Cost
- Taste
- Frequency of administration
- Pill size
- Duration of therapy
- Multiple drug therapy
- Adverse effects
- Current symptoms

Duke Center for Antimicrobial Stewardship and Infection Prevention

35

De-escalation

De-escalation is a core principle of Antimicrobial Stewardship.

Target/narrow antibiotic therapies after more clinical data returns

Stop therapy when infection has been ruled out

Goal: Reduce selective pressure, improve safety

Urine Culture: Pan-susceptible E. Coli → Narrow from Pip/Tazo to TMP/SMX → Urine culture: No Growth → STOP

Duke Center for Antimicrobial Stewardship and Infection Prevention

36

Durations (OLD)

The answer, Dr. Gilbert, is that this is highly-specialized knowledge, rarefied information that only 100% Board-Certified, USDA-inspected Infectious Diseases Doctors know. And since I'm concerned that your article might give readers the wrong impression about our scientific credibility, I'll now divulge what we've learned, and how to apply it.


To figure out how long antibiotics need to be given, use the following rules:

1. Choose a multiple of 5 (fingers of the hand) or 7 (days of the week).
2. Is it an outpatient problem that is relatively mild? If so, choose something less than 10 days. After application of our multiples rule, this should be 5 or 7 days.
3. Is it really mild, so much so that antibiotics probably aren't needed at all but clinician or patient are insistent? Break the 5/7 rule and go with 3 days. Ditto uncomplicated cystitis in young women.
4. Is it a serious problem that occurs in the hospital or could end up leading to hospitalization? With the exception of community-acquired pneumonia (5 or 7 days), 10 days is the minimum.
5. Patient not doing better at the end of some course of therapy? Extend treatment, again using a multiple of 5 or 7 days.
6. Does the infection involve a bone or a heart valve? Four weeks (28 days) at least, often 6 weeks (42 days). Note that 5 weeks (35 days) is not an option — here the 5's and 7's cancel each other out, and chaos ensues.
7. The following lengths of therapy are inherently weird, and should generally be avoided: 2, 4, 6, 8, 9, 11, 12, 13 days. Also, 3.14159265 days.

In this highly data-driven exercise, it is important also to note the number of rules — seven, as in days of the week.

<https://blogs.watch.org/hiv-id-observations/index.php/how-to-figure-out-the-length-of-antibiotic-therapy/2010/10/22/>

Paul E. Sax, MD
Contributing Editor
HEALTH CARE SPECTRUM
INFECTIOUS DISEASES




37

NEW: Trials comparing short- vs. longer-course antibiotics have shown short-course is just as effective

Disease	Short	Long
Community-acquired pneumonia	3-5 days	7-10 days
Nosocomial pneumonia (HAP/VAP)	< 8 days	10-15 days
Pyelonephritis	5-7 days	10-14 days
Intraabdominal infection	4 days	10 days
Acute exacerbation of chronic bronchitis (AECB) and COPD	≤ 5 days	≥ 7 days
Acute bacterial sinusitis	5 days	10 days
Cellulitis	5-6 days	10 days
Chronic osteomyelitis	42 days	84 days

5 is the new 7

Spillberg B. JAMA Intern Med 2016;176(8):1254-1255.



38

WHAT IS ANTIMICROBIAL STEWARDSHIP?



dcasip.medicine.duke.edu




39

IDSA/SHEA/PIDS definition

“coordinated interventions designed to improve and measure the appropriate use of [antibiotic] agents by promoting the selection of the optimal [antibiotic] drug regimen including dosing, duration of therapy, and route of administration.”

-- Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases Society (PIDS)

Barlam et al. *CID* 2016; 62(10): e51-77.
Fishman et al. *ICHE* 2012; 33:322-7.



40

Antimicrobial Stewardship Program

Decision support for prescribers of antimicrobials.

Coordinated program


Multidisciplinary teams

- MD, PharmD, RN, micro, IP, IT


Multi-level interventions:

- Educational
- Systems-based vs. 1:1
- Technology
- Active vs. Passive

I got your back, man.



Dellit et al. *Clin Inf Dis*. 2007;44(2):159-177.



41

Goals of Antimicrobial Stewardship

Primary:

- Improve quality and increase safety through appropriate use of antimicrobials
- Improve therapeutic choices (underuse)
- Reduce unnecessary use (overuse)


Secondary:

- Decrease emergence of resistance


Desirable “side effects” from an ASP:

- Decrease costs for health system
- Satisfy regulatory requirements (2017)

The goal is NOT to decrease antibiotic use...
It's to IMPROVE antibiotic use!



Moshing and Anderson. *Curr Infect Dis Rep* 2012



42

Resources for Inpatient Stewardship

IDSA/SHEA guidelines on Implementing an ASP (2009, 2016); *CID* 2016;62(10):e51–e77

CDC Core Elements Document(s) (2014, 2019, 2022 "priorities"); <https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf>

The Joint Commission Standard (2017, 2022); <https://www.jointcommission.org/resources/patient-safety-topics/infection-prevention-and-control/antibiotic-stewardship>

CMS Condition of Participation (2020): Federal Register 9/30/2019

Duke Center for Antimicrobial Stewardship and Infection Prevention

43

"Action" for inpatient ASPs

LOTS of potential AS strategies suggested in Guidelines

Must be tailored to institutional need and priorities

AVOID: overtaxed ASP personnel

CID 2016;62(10):e51–e77

Strength of Rec	Strategies
Strong	<ul style="list-style-type: none"> Preauthorization/restriction Prospective audit & feedback CD-focused intervention PK monitoring (AG) IV/PO switch Duration-focused intervention
Weak	<ul style="list-style-type: none"> Facility-specific guidelines Syndrome-specific intervention Time-out/Auto Stop Computerized Decision Support PK monitoring (Vanco) Alternate dosing for Beta Lactams Penicillin allergy assessments Stratified antibiograms Cascaded reporting of susceptibilities Rapid diagnostics: virus, blood culture Serial procalcitonin in ICU sepsis Fungal markers in Hem malignancy Febrile Neutropenia guidelines Antifungals in immunocompromised DOT>DDD AU data
Good Clinical Practice	<ul style="list-style-type: none"> Cost > purchasing data Choose clinical outcome metrics wisely Promote AS in SNFs, NICUs, terminally ill
Rec Against	<ul style="list-style-type: none"> Antibiotic Cycling Didactic education alone

44

CDC: What to Do? 2019

Table. The Core Elements of Hospital Antibiotic Stewardship Programs and the Priorities for Hospital Core Element Implementation.

Core Element	Priority
Hospital Leadership Commitment	1. Dedicate FTE
Accountability	2. Accountable leaders
Pharmacy/Stewardship Expertise	3. Pharmacist
Action	4. Act: Do something
Tracking	5. Track: AU Rates + resistance + HAls
Reporting	6. Share data back
Education	7. Do some education

Duke Center for Antimicrobial Stewardship and Infection Prevention

45

US Hospitals meeting CDC's Core Elements of AS

97%
4949/5116

<https://arpsp.cdc.gov/profile/stewardship>

HOSPITALS IMPLEMENTING ALL 7 CORE ELEMENTS IN ALL STATES OVER TIME

46

CDC 2022 "Priorities for Core Elements Implementation"

<https://www.cdc.gov/antibiotic-use/core-elements/hospital/priorities.html>

Core Element	Priority
Hospital Leadership Commitment	1. Dedicated FTE AS in contract/performance evaluation
Accountability	2. Accountable leaders: physician and pharmacist
Pharmacy/Stewardship Expertise	3. Expertise: in ID, or certificate
Action	4. Do something: "Core" strategies (PA or PAF) + Local GL
Tracking	5. Track: AU Rates (via NHSN) + resistance + HAls
Reporting	6. Share data back: annual, monitor adherence to local GL
Education	7. Do some education

Duke Center for Antimicrobial Stewardship and Infection Prevention

47

North Carolina and USA, 2022

<https://arpsp.cdc.gov/profile/stewardship>

HOSPITAL PRIORITY ELEMENT REPORTING IN NORTH CAROLINA

Priority Element	Implementing Individual Elements	Implementing All 6 Priority Elements
All 6 Priority Elements	30.5%	79.5%
Leadership Commitment Priority Element	88.8%	40.2%
Accountability Priority Element	69.2%	30.8%
Pharmacy Expertise Priority Element	76.9%	23.1%
Action Priority Element	63.2%	85.9%
Tracking Priority Element	63.2%	36.9%
Reporting Priority Element	38.5%	61.5%

National Estimates of Hospitals Meeting, 2022

Priority Element	Implementing Individual Elements	Implementing All 6 Priority Elements
All 6 Priority Elements	10	66.5
Leadership Commitment Priority Element	66.5	64.9
Accountability Priority Element	64.9	76.9
Pharmacy Expertise Priority Element	76.9	72.5
Action Priority Element	72.5	47.8
Tracking Priority Element	47.8	28.1
Reporting Priority Element	28.1	61.5

48

Priority "Actions" for Inpatient Stewardship

Preauthorization/restriction (before prescribing)

- Can be time/personnel intensive
- Must think through unintended consequences and process snafus
- Not for all hospitals – local culture plays a role
- Best if for targeted agents (not every antibiotic order...)

Post-prescription audit and feedback (after prescribing)

- Front-line stewardship "experts" actively review patients on antibiotics and give feedback to prescribers 1:1
- Time intensive, but effective
- Better for personal relationships
- Need ID "back up" for tough cases

"Handshake" Stewardship or Stewardship Rounds

Face to face is better than phone/pager/zoom.

CID 2016;62(10):e51–e77
Hurst A et al. PIDJ 2016;35(10):1104-10
Seidelman. CID 2022; 74(11):1986-1992

49

iVENTs

"The Grind"

- Antibiotic streamlining/de-escalation (35%)
- Dose/Drug (25%)
- Duration/Discontinuation (17%)
- Allergy assessment (9%)
- ID consult rec (5%)
- IV/PO switch (3%)

Interventions FY20

50

Reporting Priority for Inpatient Stewardship

Facility-specific treatment recommendations for common clinical condition(s)

AMERICAN THORACIC SOCIETY DOCUMENTS

Diagnosis and Treatment of Adults with Community-acquired Pneumonia

An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

© 2019 by American Thoracic Society and Infectious Diseases Society of America

- Local Patient Population(s)
- Local Formulary
- Local Antibigram
- Typically requires pharmacy + physician input, approved by hospital or system committee
- Dissemination
- Education
- Integration into ordersets/pathways
- **Assessment of Adherence (2023)

51

"Tracking" Antibiotic Use

<https://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf>

NHSN AU Option for acute care hospitals

- ONLY uses electronic data from EHRs (no manual surveillance and no subjective components)

Rate: Days of therapy (DOT) per 1,000 days present

- DOT = calendar days of treatment regardless of number of doses
- Separate drugs counted separately
- Denominator is DIFFERENT than patient days

Data is stratified by Agent, Route, Unit location

Benchmark: Standardized Antimicrobial Administration Ratio (SAAR)

52

REVISED TJC Inpatient Stewardship Standards: Jan 2023

MM.09.01.01

Standards related to measurement of AU:

- 15. The antibiotic stewardship program documents the evidence-based use of antibiotics in all departments and services of the hospital.
- 16. The antibiotic stewardship program monitors the hospital's antibiotic use by analyzing data on days of therapy per 1000 days present or 1000 patient days, or by reporting antibiotic use data to the National Healthcare Safety Network's Antimicrobial Use Option of the Antimicrobial Use and Resistance Module.
- 19. The antibiotic stewardship program evaluates adherence (including antibiotic selection and duration of therapy, where applicable) to at least one of the evidence-based guidelines the hospital implements.

Note 1: The hospital may measure adherence at the group level (that is, departmental, unit, clinician subgroup) or at the individual prescriber level.

Note 2: The hospital may obtain adherence data for a sample of patients from relevant clinical areas by analyzing electronic health records or by conducting chart reviews.

53

Benchmarking AU between Hospitals

What you want to measure:

- Prescribing practices and decision-making

What you get:

- Tonnage or measure of abx exposure – not "appropriate" abx

Problems:

- Case mix
- Hospital size
- Clinical service lines (e.g. surgical specialties, types of ICUs, moms/babies)
- Assume more = bad (not always true clinically)

Should be viewed as a starting point for further investigation and explanation.

Stratim. Polk. Expert Rev Anti Infect Ther 10 (4):445-57.
Stanleygen. CID 2016;63(10):1273–80

54

NHSN Standardized Antibiotic Administration Ratio (SAAR)

Standardized Antibiotic Administration Ratio: Observed/Expected based on NHSN baseline + limited risk adjustment with information from annual survey

- Heavily stratified: Pediatric (8), NICU (7), and Adult (7) agent groups; Pediatric (5), NICU (3), and Adult (8) NHSN unit types. No benchmarks for highly specialized units.

Baseline 2017

- Most current SAAR Targets are pooled mean + percentiles reported in annual report (2021)

<https://www.cdc.gov/nhsn/databrowser/antibio-saar.html>
<https://www.cdc.gov/nhsn/pdf/ss-analysis/issuereport/antibio-saar-guide-508.pdf>

Broad spectrum antibacterial agents predominantly used for hospital-onset infections used in adult SAAR wards

Facility Org ID	SAAR Type 2017 Baseline	Location	Summary Year/Month	CDC Location	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	SAAR p value	95% Confidence Interval	SAAR Percentile
10009	Adult_BSHO_Vard_2017	MEDSURG64	2022M11	IN ACUTE WARD MS	45	36.819	320	1.222	0.1852	0.902, 1.621	64

Duke Center for Antimicrobial Stewardship and Infection Prevention

55

Antibiotic Use And Resistance Reporting Is Now Required for Acute Care Hospitals

The requirement was in the 2023 Inpatient Prospective Payment System rule from CMS. The requirement is under the Promoting Interoperability program standard "Public Health and Clinical Data Exchange Objective"

<https://www.federalregister.gov/documents/2022/08/10/2022-16472/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the-h-623>

Not only AU Option, but also the NHSN AR module

- Hospitals that don't participate lose their incentive (\$\$\$) by Jan 2025 (for reporting year 2024).

Page 49335
Slide: Arjun Srinivasan

Duke Center for Antimicrobial Stewardship and Infection Prevention

56

Measuring "Appropriate" or "Optimal" antimicrobial use in the Inpatient Setting

Will generally introduce subjectivity and require individual case review by a trained individual

More focused to syndrome and/or drug

- "MUE" + adherence with local guidelines

Typically sampled prevalence or retrospective study, but can be prospective and integrated into intervention delivery

Big time personnel effort

<https://www.ncas-australia.org/ncas-publications>

Duke Center for Antimicrobial Stewardship and Infection Prevention

57

CMS: ASP required in Long-term Care

CMS Requirement for Long-term Care ASPs

Barriers to Implementation of AS in LTC:

- Knowledge/Evidence
- Expertise
- Different stakeholders + processes of care than acute care
- Personnel and turnover

Duke Center for Antimicrobial Stewardship and Infection Prevention

58

Resources for LTC Stewardship

JAMDA
Journal of Antimicrobial Stewardship and Infection Prevention

Special Article
Template for an Antibiotic Stewardship Policy for Post-Acute and Long-Term Care Settings

Robin LP, Jump MD, PhD^{1,2,3}, Swati Gaur MD, MBA, CMD¹, Megan J. Katz MD¹, Christopher J. Crutch MD, PhD^{1,2}, Chamea Danyani MD¹, Muhammad S. Ashraf MBBS¹, Elizabeth Frenzel MPH¹, Steven J. Schaefer RN, MPH, MSN, CEC, RHM¹, Philip Staine MD, MPH¹, David Nace MD, MPH, CMD¹ on behalf of the Infection Advisory Committee for AMDA—The Society of Post-Acute and Long-Term Care Medicine

CDC Core Elements

AHRQ Guide

CMS Standard Interpretive Guidance

Duke Center for Antimicrobial Stewardship and Infection Prevention

59

Examples of Stewardship "Action" in LTC

Antibiotic use protocols – "Minimum Criteria" for Abx starts

Test/diagnostic stewardship

- UA/culture
- C. difficile

Durations/length of therapy and guides for common infection

- UTI
- Pneumonia
- Cellulitis

"Active monitoring" as an alternative to empiric antibiotics in patients who have a clinically undifferentiated problem (e.g. "not at baseline")

Duke Center for Antimicrobial Stewardship and Infection Prevention

60

Example: Antibiotic Use Protocol

Target: nursing assessment
Identifies “red flag” symptoms
Includes “notes” that identify key areas for baseline knowledge
Provides next steps alternative (other than an antibiotic)

AHRQ Toolkit: “Minimum Criteria for Common Infections”

Minimum Criteria for Initiating Antibiotics for a Skin and Soft Tissue Infection
Initiate antibiotics if the following criteria are met:
○ New or increasing purulent drainage at a wound, skin, or soft-tissue site
OR
○ At least one of the following:
• Fever (temperature >100°F [37.8°C] or two repeated temperatures of 99°F [37°C]), or
• Tenderness, or
• Erythema, or
• Swelling that is new or increasing at the affected site

Notes:
1. For residents that regularly take a lower temperature, use a temperature of 2°F (1°C) above the baseline as a reference of fever.
2. Repeat sooner as a visit and therefore does not require antibiotics but appropriate watch.
3. Order is not a stand-alone criterion for treatment with antibiotics.
4. Deep-seated infections such as abscesses may present with similar signs/symptoms.
5. Underlying osteomyelitis should be considered when managing a resident with an infected tubular or drainage site.
6. Thrombotic thrombocytopenic syndrome should be considered when a resident presents with an erythematous or swollen leg.
7. These criteria do not apply to residents with trauma.
8. Great care must be taken for cellulitis or skin tears.

If any of the minimum criteria are met, consider initiating the following:
• Assess vital signs, including temp, every _____ hours for _____ hours, and/or
• Notify Physician/NP/PA if symptoms worsen or if unresolved as _____ hours.

Regardless of whether the minimum criteria are met or not, consider initiating the following:
• For decubiti or prior to changing dressing changes, consider using antiseptics or other pain relief as needed.

Duke Center for Antimicrobial Stewardship and Infection Prevention

61

Active Monitoring

This is an active process
More frequent vital signs
Oral hydration
Assess for pain, changes in medicine, other reasons like a bad night's sleep (or disagreement with a loved one)

Order Set

- Obtain vital signs (BP, Pulse, Resp Rate, Temp, Pulse Ox) every ____ hours for ____ days.
- Record fluid intake each shift for ____ days.
- Notify physician if fluid intake is less than ____ cc daily.
- Offer resident ____ ounces of water / juice every ____ hours.
- Notify physician, NP, or PA if condition worsens, or if no improvement in ____ hours.
- Obtain the following blood work _____.
- Consult pharmacist to review medication regimen.
- Contact the physician, NP, PA with an update on the resident's condition on _____.

Duke Center for Antimicrobial Stewardship and Infection Prevention

Nace et al., JAMA 2014;15:133-139

62

Potential Policies & Procedures: UTI

- Concerns about stinky or cloudy urine should lead to increased hydration and perhaps, watchful waiting/careful observation.
- Automatic review of all medication changes by outside providers.
- Send residents to the Emergency Room with a note clearly stating what you are (and are not) worried about.

Duke Center for Antimicrobial Stewardship and Infection Prevention

NIAID Public Health Image

63

Potential Policies & Procedures: UTI

- Clear criteria for collecting a urine sample
- Documented protocol for proper sample collection and handling
- Communication tools when nurses call a covering provider
- Proactively talk to residents and their family members—on admission and during change of status

Duke Center for Antimicrobial Stewardship and Infection Prevention

NIAID Public Health Image

64

Resources for Outpatient Stewardship

Outpatient Standard for TJC (Jan 2020)

4 “Core Elements”

Type of outpatient practice setting is highly varied

- Adult/pediatric
- Specialty clinics
- Retail clinics
- Urgent Care

https://www.cdc.gov/antibiotic-use/community/pdfs/16_268900-A_CoreElementsOutpatient_508.pdf

Duke Center for Antimicrobial Stewardship and Infection Prevention

Clinician Checklist for Core Elements of Outpatient Antibiotic Stewardship
CDC recommends that outpatient clinicians take steps to implement antibiotic stewardship activities. Use this checklist as a baseline assessment of policies and practices that are in place. Then use the checklist to review progress in expanding stewardship activities on a regular basis (e.g., annually).

COMMENTARY
1. Do you have written policies in place and accessibility for optimizing antibiotic prescribing and patient care related to antibiotics?
If yes, indicate which of the following are in place (select all that apply):
□ Use of shared decision-making in regard to antibiotic stewardship.

ACTION
2. Have you implemented at least one practice to improve antibiotic prescribing?
If yes, indicate which practice you use. (Select all that apply):
□ Use electronic health record (EHR) and decision support systems.
□ Implement antibiotic prescribing guidelines or antibiotic stewardship, when applicable.

TRACKING AND REPORTING
3. Do you monitor at least one aspect of antibiotic prescribing?
If yes, indicate which of the following are being tracked. (Select all that apply):
□ Antimicrobial antibiotic prescribing practices.
□ Participation in voluntary medical product and quality improvement activities to track and measure antibiotic prescribing.

EDUCATION AND SUPPORT
4. Do you provide education to patients and seek out continuing education on antibiotics?
If yes, describe how you provide antibiotic stewardship education. (Select all that apply):
□ Use effective communication strategies to educate patients about when antibiotics are and are not needed.
□ Educate about the correct name of antibiotic treatment.
□ Provide patient education resources.

65

“Action” in Outpatient Stewardship

Most literature in Primary or Urgent Care

Peer comparison + data feedback
= Most commonly done for upper respiratory infection
= Identify diagnoses (e.g. viral URI) for which antibiotics should not be given. Benchmark % given abx with peers
= HEDIS measures (primary care and pediatrics)

Suggested alternatives
Accountable justification
“Nudge” letter/poster
Education combined with the above

We want to give you some important information about antibiotics.
Antibiotics, like penicillin, fight infections due to bacteria that can cause some serious illnesses. But these medicines can cause side effects like skin rashes, diarrhea, or yeast infections. If your symptoms are from a virus and not from bacteria, you won't get better with an antibiotic, and you could still get these bad side effects.
Antibiotics also make bacteria more resistant to them. This can make future infections harder to treat. This means that antibiotics might not work when you really need them. Because of this, it is important that you only use an antibiotic when it is necessary to treat your illness.
How can you help? Carefully follow your doctor's instructions. He or she will tell you if you should or should not take antibiotics.
When you have a cough, sore throat, or other illness, your doctor will help you select the best possible treatments. If an antibiotic would do more harm than good, your doctor will explain this to you, and may offer other treatments that are better for you.
Your health is very important to us. As your doctors, we promise to treat your illness in the best way possible. We are also dedicated to avoid prescribing antibiotics when they are likely to do more harm than good.
If you have any questions, please feel free to ask your doctor, nurse, or pharmacist.

Becher, JAMA 2013;309(22):2345-2352
Meeker, JAMA 2016; 315(8):662-670
Meeker, JAMA Intern Med. 2014;174(3):425-431.

Duke Center for Antimicrobial Stewardship and Infection Prevention

66

HOT in Stewardship RN


Diagnostic Stewardship
 * SHEA Task Force for Diagnostic Stewardship (e.g. Urine testing, C. difficile, Blood cultures)
 * Fabre ICHE 2023 44(2), 178-185. doi:10.1017/ice.2023.5

Transitions of Care, including antibiotic durations at discharge
 * Mercurio. JAMA Network Open 2022 5(5):e2211331. doi: 10.1001/jamanetworkopen.2022.11331

Outpatient parenteral antibiotic therapy (OPAT) to Complex Outpatient Antibiotic Therapy (COPAT)
 * JAC 74(6):2119-2121

Management bundles (e.g. Gram negative BSI)
 * Appropriate risk assessment/stratification, use of ID consultation
 * Oral transition, short durations, follow up blood culture guidance
 * Heil Open Forum Infect Dis. 2021 8(10): ofab434.

Diversity, Equity, and Inclusion in antibiotic prescribing



67


A case, continued.

86F with history of dementia, diabetes, and poor functional status presents from SNF with confusion, fever.

Day 3: Remains on vancomycin and zosyn. Progress note still says "sepsis." BCx negative. Awake/interactive.

Clinical pharmacist reviews the patient for vancomycin dosing, sees urine +E. coli susceptible to multiple oral and intravenous agents.

Contacts the provider.




68

Clinical Discussion

- Does the patient have an infection that requires antibiotics?
- Have I ordered appropriate cultures before starting antibiotics?
What empirical antibiotic therapy should I initiate?
- A day or more has passed.
Can I stop antibiotics?
Can I narrow therapy?
Can I change from IV to oral therapy?
- What duration of antibiotic therapy is needed for this patient's diagnosis?


Tamma PD et al. JAMA. 2019;321(2):139-140.



69

Summary

Antibiotics are life-saving medicines that are often misused. Antimicrobial decision-making is complex. Optimized antimicrobial use through antimicrobial stewardship protects patients from unintended consequences. Antimicrobial use affects individuals AND populations. Healthcare exposed populations are the most at risk. Antimicrobial Stewardship Programs are required in US healthcare facilities and a key component of infection prevention.



70

THANK YOU!

Rebekah.Moehring@duke.edu






71

Antibiotics with Gram Positive (+) Activity

<i>S. aureus</i>	MRSA	VRE	<i>E. faecalis</i>
Nafcillin/Oxacillin			Ampicillin
Ampicillin/Sulbactam, Piperacillin/Tazobactam			Ampicillin/Sulbactam, Piperacillin/Tazobactam
Cephalosporins	Ceftaroline (only)		
Carbapenems (Fluoroquinolones)			
Vancomycin	Vancomycin		Vancomycin
Clindamycin	Clindamycin +/-		
Linezolid	Linezolid	Linezolid	Linezolid
Daptomycin	Daptomycin	Daptomycin	Daptomycin
Telavancin	Telavancin		
TMP-SMX	TMP-SMX		
Dalvabancin, Ortavancin	Dalvabancin, Ortavancin		



72

Antibiotics with Gram Negative (-) Activity

<i>E. coli</i>	<i>K. pneumoniae</i>	<i>Enterobacter</i>	<i>P. aeruginosa</i>
(Ampicillin)			
(Amp/subl)	(Amp/subl)		
Pip/Tazo	Pip/Tazo	Pip/Tazo	Pip/Tazo
Cephalosporins	Cephalosporins	3 rd , 4 th , 5 th gen.	Ceftaz/Cefepime
Carbapenems	Carbapenems	Carbapenems	Imp, Mero, Dori
Aztreonam	Aztreonam	Aztreonam	Aztreonam
Aminoglycosides	Aminoglycosides	Aminoglycosides	Amino-glycosides
Fluoroquinolone	Fluoroquinolone	Fluoroquinolone	Cipro and Levo
Trimeth/Sulf	Trimeth/Sulf	Trimeth/Sulf	

Duke Center for Antimicrobial Stewardship and Infection Prevention

73

Antibiotic use assoc. with CDI risk – even in patients who don’t get Abx!

46-month, single center retrospective study

255 of 34,298 patients developed CDI (Incidence rate, 5.95 per 10,000 ptd)

Each 10% increase in ward-level antibiotic exposure was associated with a 2.1 per 10,000 increase in CDI

After adjustment for patient-level RFs, effect persisted: Relative risk, 1.34 (1.16-1.57) per 10% increase in days of therapy

JAMA Intern Med. 2015;175(4):626-633

Figure 2. Ward Clostridium difficile Infection (CDI) Incidence and Antibiotic Use Across Hospital Wards and Among Patients With and Without Direct Antibiotic Exposure

Each pair of numbered symbols represents the incidence of C difficile infection among the subset of patients who received antibiotics (diamonds) and those who did not (circles) within a given ward. For correspondence of ward identifiers, see Table 2. DDDs indicates days of therapy.

Duke Center for Antimicrobial Stewardship and Infection Prevention

74